Healthcare Providers, Patient Advocates,
Government Agencies and Industry Will Discuss Critical Issues
Facing SCD Community During National Sickle Cell Disease Awareness
Month
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced
that it will host the Annual Sickle Cell Disease (SCD) Therapeutics
Conference, which will take place on September 14, 2017, at the
Four Seasons Hotel in New York. This unique conference is being
held in conjunction with National SCD Awareness Month and will
feature discussions among leading physicians, patient advocates,
government agencies, public and private companies, and healthcare
investment analysts. Conference participants will discuss issues
and trends in SCD treatment including the daily experience of
living with SCD, the burden and cost of SCD in the United States,
the role of novel clinical endpoints in new drug development,
innovative SCD care models, and hemolysis and its clinical
consequences. The conference will also feature updates from the
U.S. Food and Drug Administration (FDA), American Society of
Hematology (ASH), and the Sickle Cell Disease Association of
America (SCDAA), as well as corporate presentations from industry
leaders.
“SCD is a critical health problem that requires the attention of
a broad range of stakeholders in the SCD community. As host of this
year’s Sickle Cell Disease Therapeutics Conference, we look forward
to coming together as a community to highlight the daily struggles
facing individuals living with SCD and to discuss innovative
solutions that could dramatically improve their healthcare and
quality of life,” said Ted W. Love, M.D., president and chief
executive officer of GBT. “Opportunities to listen to the needs of
the community via the SCD Therapeutics Conference and other
awareness events during SCD Awareness Month inspire our company to
remain laser-focused on our goal of bringing a potentially
disease-modifying therapeutic option to patients.”
The SCD Therapeutics Conference will feature the following
speakers:
- Ann Farrell, M.D., Division Director, Division of Hematology
Products, Office of Hematology and Oncology Drug Products at the
Center for Drug Evaluation and Research, FDA
- Mary Hulihan, Dr.P.H., Health Scientist, Epidemiology and
Surveillance Branch, Division of Blood Disorders, National Center
on Birth Defects and Developmental Disabilities, Centers for
Disease Control and Prevention
- Biree Andemariam, M.D., Associate Professor of Medicine,
University of Connecticut Health; Founding Director, New England
Sickle Cell Institute; CMO, SCDAA
- Kenneth Ataga, M.B.B.S., Professor of Medicine, Director,
Comprehensive Sickle Cell Program, University of North Carolina at
Chapel Hill
- Victor R. Gordeuk, M.D., Professor of Medicine, Director,
Sickle Cell Center, University of Illinois at Chicago
- Julie Kanter-Washko, M.D., Associate Professor and Director
Sickle Cell Disease Research and the Lifespan Comprehensive Sickle
Cell Center, Medical University of South Carolina
- Sophie M. Lanzkron, M.D., M.H.S., Director of the Sickle Cell
Center for Adults, Associate Professor Medicine and Oncology,
Division of Hematology, Johns Hopkins University School of
Medicine
- Diane Nugent, M.D., Clinical Professor and Chief of Hematology,
Department of Pediatrics, UC Irvine School of Medicine; Founder,
Medical Director, Center for Inherited Blood Disorders
- Betty S. Pace, M.D., Professor of Pediatrics, Francis J.
Tedesco Distinguished Chair and Interim Chief, Division of
Pediatric Hematology/Oncology, August University Medical College of
Georgia
- Wally R. Smith, M.D., Professor, Director of the Adult Sickle
Cell Program, Virginia Commonwealth University
- Sonja L. Banks, President and COO, SCDAA
- LaTasha Lee, Ph.D., M.P.H., Manager, Sickle Cell Policy and
Programs, ASH
- Lakiea Bailey, Ph.D., Executive Director, Sickle Cell Community
Consortium
- Mary E. Brown, President and CEO, Sickle Cell Disease
Foundation of California
- Donnette Carroll, President, Sickle Cell Thalassemia Patients
Network (SCTPN)
- Gary A. Gibson, President and CEO, The Martin Center Sickle
Cell Initiative
- TaLana Hughes, M.P.H., Executive Director, Sickle Cell Disease
Association of Illinois (SCDAI) and Tiahna Hughes, patient
advocate
- Karen L. Proudford, Ph.D., President, William E. Proudford
Sickle Cell Fund
Conference attendees will also hear presentations from nine
public and private companies currently developing treatment options
for patients with SCD: ApoPharma, Bioverativ, bluebird bio, Emmaus
Life Sciences, EpiDestiny, GBT, Imara, Modus Therapeutics and
Prolong Pharmaceuticals.
GBT will premiere a video at the conference that captures one
family’s experience with SCD. The short video, which features the
Zuttah family, Jeffrey “Jeff” Zuttah, his brother Jeremy, and his
mother Christine, chronicles Jeff’s challenges and triumphs living
with SCD. Following the conference, GBT will make this video
available to the public on its social media channels.
To help ensure that those who are unable to attend the
conference can benefit from presentations and information sharing
at the conference, GBT is collaborating with Sickle Cell Warriors,
an SCD community organization, to livestream the conference on the
organization’s Facebook page at
http://www.facebook.com/SickleCellWarriors. GBT will also post
videos following the event on its corporate YouTube channel. For
more information on the conference visit
http://www.scdconference.com.
In addition, during the month of September, GBT will partner
with a number of SCD organizations to sponsor local education
events, awareness walks, and social media efforts to help raise
awareness of the disease. As part of these efforts, GBT will
participate in the SCDAA Twitter Party and collaborate with Sickle
Cell 101, a non-profit advocacy organization, to distribute content
on the GBT Twitter channel, @GBT_news, that profiles the struggles,
accomplishments and advocacy work of SCD patients and
caregivers.
About Sickle Cell DiseaseSCD is a growing
health problem that currently affects approximately 100,000
Americans. By 2050, the number of people with SCD is expected to
increase by 30 percent globally. SCD is a lifelong inherited
disease that disproportionately affects African-Americans and
Hispanic-Americans. SCD impacts one out of every 365 African
American births, and one out of every 16,300 Hispanic-American
births. SCD is a lifelong blood disorder that occurs when a person
inherits a sickle cell gene and another abnormal hemoglobin gene,
one from each parent. In people with SCD, red blood cells (RBCs)
lose their normal disc shape and become sickle-shaped and rigid.
Sickle-shaped RBCs get stuck in small blood vessels and block the
flow of blood and oxygen to the body. Beginning in childhood, SCD
patients suffer unpredictable and recurrent episodes or crises of
severe pain due to blocked blood flow to organs, which often lead
to psychosocial and physical disabilities. This blocked blood flow,
combined with hemolytic anemia, can eventually lead to stroke,
multi-organ damage and premature death. Over the last century,
several important discoveries have led to improved diagnosis and
treatments, but people with the disease still have severe
complications and shorter life expectancy.
About Global Blood
Therapeutics Global Blood Therapeutics, Inc. is a
clinical-stage biopharmaceutical company dedicated to discovering,
developing and commercializing novel therapeutics to treat grievous
blood-based disorders with significant unmet need. GBT is
developing its lead product candidate, GBT440, as an oral,
once-daily therapy for sickle cell disease. GBT is also
investigating GBT440 for the treatment of hypoxemic pulmonary
disorders in two ongoing Phase 2a studies in patients with
idiopathic pulmonary fibrosis. To learn more, please
visit www.globalbloodtx.com and follow the company on
Twitter: @GBT_news.
Please note that we do not necessarily sponsor, endorse or
approve any third-party information, websites, or pages directly or
indirectly linked by or through this press release, and we do not
incorporate by reference any materials that appear in any such
sites or links.
Forward-Looking Statements Statements we
make in this press release may include statements that are not
historical facts and are considered forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
We intend these forward-looking statements, including statements
regarding the therapeutic potential and safety profile of GBT440,
our ability to implement our clinical development plans for GBT440
in both SCD and hypoxemic pulmonary disorders, our ability to
generate and report data from our ongoing studies of GBT440,
regulatory review and actions relating to GBT440, our ability to
generate and report data from the new single-dose cohort in younger
pediatric participants and the timing of these events, to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect our current
views about our plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to us and on assumptions we have made. We can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved, and furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control including, without limitation, the risks that
our clinical and preclinical development activities may be delayed
or terminated for a variety of reasons, that regulatory authorities
may disagree with our clinical development plans or require
additional studies or data to support further clinical
investigation of our product candidates, and that drug-related
adverse events may be observed in later stages of clinical
development, along with those risks set forth in our Annual Report
on Form 10-K for the fiscal year ended December 31,
2016 and in our Quarterly Report on Form 10-Q for the quarter
ended June 30, 2017, as well as discussions of potential
risks, uncertainties and other important factors in our subsequent
filings with the U.S. Securities and Exchange Commission.
Except as required by law, we assume no obligation to update
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
investor@globalbloodtx.com
Julie Normart (media)
Pure Communications
415-946-1087
media@globalbloodtx.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2023 to Mar 2024